You have read all your free articles, to continue reading subscribe to read the rest of this content.
Swiss-Finnish Aurealis Therapeutics has entered into an exclusive license and collaboration agreement with Xbiome for the clinical development and commercialization of Aurealis investigational Diabetic Foot Ulcer (DFU), other chronic wounds, and inflammatory disease therapy AUP-16 in Greater China. Already a subscriber Login You have read all your free articles, to…
Calliditas Therapeutics has announced that the U.S. Food and Drug Administration has extended the PDUFA goal date for its New Drug Application (NDA) seeking accelerated approval for Nefecon to December 15, 2021. In March 2021 Calliditas filed for FDA approval using the Accelerated Approval PrograAlready a subscriber Login You have…
Orion’s collaboration partner Bayer has announced the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for the oral androgen receptor inhibitor (ARi) darolutamide in combination with docetaxel for the treatment of metastatiAlready a subscriber Login You have read all your…
The obesity research unit will be co-located with the Novo Nordisk type 1 diabetes research unit at the company's research centre in Seattle, which opened in 2009. The new unit is a result of Novo Nordisk's increasing focus on treatment of obesity with the aim to identify novel approaches and taAlready…
